| |
| |
|
| Insider
Information: |
Altshuler David |
| Relationship: |
EVP, Chief Scientific... |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
25,813 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$11,436,450 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
25,813 |
|
|
| Total
Value |
$11,436,450 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Vertex Pharmaceuticals Inc |
VRTX |
EVP, Chief Scientific... |
2024-05-15 |
25,813 |
2014-07-31 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
157 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 5 of 7
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-05-12 |
4 |
AS |
$287.33 |
$374,678 |
D/D |
(1,304) |
28,902 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-05-15 |
4 |
AS |
$274.98 |
$23,318 |
D/D |
(82) |
28,902 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-08-03 |
4 |
AS |
$276.84 |
$648,290 |
D/D |
(2,330) |
28,902 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-08-03 |
4 |
OE |
$86.52 |
$201,592 |
D/D |
2,330 |
31,232 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-08-06 |
4 |
OE |
$155.57 |
$190,262 |
D/D |
1,223 |
30,125 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-08-06 |
4 |
AS |
$270.12 |
$331,663 |
D/D |
(1,223) |
28,902 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-11-16 |
4 |
AS |
$222.45 |
$8,492 |
D/D |
(38) |
28,902 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
32,453 |
61,355 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2021-02-10 |
4 |
D |
$214.16 |
$636,912 |
D/D |
(2,974) |
58,381 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2021-02-11 |
4 |
AS |
$210.42 |
$1,112,274 |
D/D |
(5,283) |
53,098 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2021-02-17 |
4 |
D |
$211.75 |
$1,321,320 |
D/D |
(6,240) |
46,858 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2021-02-18 |
4 |
AS |
$210.11 |
$1,657,590 |
D/D |
(7,825) |
39,033 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2021-02-24 |
4 |
D |
$217.57 |
$525,649 |
D/D |
(2,416) |
36,617 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2021-02-25 |
4 |
AS |
$211.58 |
$646,139 |
D/D |
(3,028) |
33,589 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2021-05-17 |
4 |
AS |
$215.31 |
$17,093 |
D/D |
(79) |
33,589 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2021-11-15 |
4 |
AS |
$186.80 |
$6,365 |
D/D |
(34) |
33,589 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
32,108 |
65,697 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-02-02 |
4 |
AS |
$247.73 |
$1,171,842 |
D/D |
(4,660) |
65,697 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-02-02 |
4 |
OE |
$86.52 |
$403,183 |
D/D |
4,660 |
70,357 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-02-10 |
4 |
D |
$237.74 |
$836,369 |
D/D |
(3,518) |
62,179 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-02-11 |
4 |
AS |
$233.92 |
$539,837 |
D/D |
(2,297) |
59,882 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-02-14 |
4 |
AS |
$232.02 |
$567,057 |
D/D |
(2,444) |
57,438 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-02-17 |
4 |
D |
$232.51 |
$799,602 |
D/D |
(3,439) |
53,999 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-02-18 |
4 |
AS |
$229.22 |
$995,949 |
D/D |
(4,312) |
49,687 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-02-24 |
4 |
D |
$227.86 |
$1,375,819 |
D/D |
(6,038) |
43,649 |
0 |
- |
|
157 Records found
|
|
Page 5 of 7 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
